T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
AssigneeBiokine Therapeutics Ltd.
InventorsAmnon Peled, Michal Begin, Katia Beider, Michal Abraham
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.
Claims25
A vaccine composition comprising:
- (i) at least one antigen, or a recombinant construct comprising a nucleic acid sequence encoding at least one antigen, the nucleic acid sequence being operably linked to at least one transcription control sequence;
- (ii) at least one pharmaceutically acceptable adjuvant comprising a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof in an amount sufficient to increase the immunogenicity of the at least one antigen;
- and (iii) a pharmaceutically acceptable carrier, excipient or diluent.
7-9. (canceled)
A method for enhancing the immunogenicity of an antigen, comprising combining the antigen with a compound having CXCR4 agonistic properties in an amount sufficient to increase the immunogenicity of said antigen.
A method for stimulating or enhancing in a subject in need thereof an immune response to an antigen, comprising administering to the subject:
- i) an immunogenic amount of the antigen, or a recombinant construct comprising a nucleic acid sequence encoding the antigen, the nucleic acid sequence being operably linked to at least one transcription control sequence, and ii) an immunogenicity-augmenting amount of a compound having CXCR4 agonistic properties in concurrent or sequential combination with said antigen.
18-21. (canceled)
A method for enhancing the immunogenicity of a tumor characterized by CXCR4 membrane expression in a subject in need thereof, comprising administering to the subject a compound having CXCR4 agonistic properties in an amount sufficient to increase the immunogenicity of said tumor.
(canceled)
A method for inducing or enhancing secretion of MIP3α from cells characterized by CXCR4 membrane expression, comprising contacting the cells with a compound having CXCR4 agonistic properties.
(canceled)
Dependencies are inferred from the claim text.